Advertisement
Document › Details
Medigene AG. (9/6/18). "Press Release: Medigene Announces Inclusion in SDAX". Planegg.
Organisation | Medigene AG (FSE: MDG1, Prime Standard) | |
Group | Medigene (Group) | |
Organisation 2 | Deutsche Börse AG | |
Today | Deutsche Börse (Group) | |
Group | Deutsche Börse (Group) | |
Product | T cell therapy | |
Product 2 | financial services | |
Person | Hofmann, Julia (ITM 202110– Head of Corp Comms before MC Services + Medigene) | |
Person 2 | Mayer, Robert (Medigene 201512– Senior Manager PR + IR before College Hill Life Sciences/Northbank Munich) | |
Medigene AG (FSE: MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies for the treatment of cancer, announces that the Medigene share will be part of the SDAX from 24 September 2018 onwards, following the restructuring of the Deutsche Börse indices. The SDAX, the smaller-cap index, is being expanded from 50 to 70 stocks. Medigene is the only biotech company in the new SDAX and has met the relevant criteria for inclusion in terms of market capitalization and free float trading volume.
Further information on Deutsche Börse's rule changes can be found online in the Equity Indices Guide at www.dax-indices.com/resources .
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene focuses on the development of personalized T cell-based therapies, with projects currently in preclinical and clinical development.
For more information, please visit medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and Veregen® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01
email: investor@medigene.com
Record changed: 2023-06-05 |
Advertisement
More documents for Medigene (Group)
- [1] Medigene AG. (11/21/23). "Press Release: Medigene AG Announces Prioritization of Pipeline and Resource Allocation as Well as Extension of Cash Runway". Planegg....
- [2] Medigene AG. (5/3/23). "Press Release: Medigene AG Reports Financial Results and Business Update for Q1 2023". Martinsried....
- [3] Medigene AG. (5/2/23). "Press Release: Medigene Acquires Worldwide, Exclusive License of CD40L-CD28 Costimulatory Switch Receptor". Planegg....
- [4] Medigene AG. (2/1/23). "Press Release: Medigene AG Appoints Pamela Keck as Vice President of Investor Relations and Corporate Communications". Planegg....
- [5] Medigene AG. (1/18/23). "Press Release: Medigene Receives $3 Million Milestone Payment from 2seventy bio". Planegg....
- [6] Medigene AG. (2/25/22). "Press Release: Dr. Selwyn Ho Appointed New CEO of Medigene". Lisbon....
- [7] BioNTech SE. (2/21/22). "Press Release: BioNTech and Medigene Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer". Mainz & Martinsried....
- [8] Medigene AG. (1/28/21). "Press Release: Focus on Solid Tumors – Discontinuation of MDG1021 Development Program". Planegg-Martinsried....
- [9] Medigene AG. (1/13/21). "Press Release: Medigene Expands Patent Protection of Its Technologies in Key Markets, the USA and Europe". Planegg-Martinsried....
- [10] Medigene AG. (11/12/20). "Press Release: Medigene Provides Q3 2020 Update". Planegg-Martinsried....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top